Risedronate in the Prevention of Osteoporosis in Postmenopausal Women

NCT00402441 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG: Risedronate (HMR4003)

Sponsor

Sanofi

Collaborators

[object Object]